The Agency’s many stakeholders, including the European institutions, the competent authorities of Member States, citizens of the European Community, patients, patient representatives and the pharmaceutical industry, will continue to have high expectations of this Agency, and the Agency is in my opinion, in a position to deliver against those expectations.